Clinical Trial Update: Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

View source ↗

Summary

The document indicates that an expanded access program for tofersen in people with SOD1-ALS has been approved for marketing, enabling broader access to the ther…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Tofersen (tofersen)

Snippet

Sponsor: Biogen | Conditions: Superoxide Dismutase 1-Amyotropic Lateral Sclerosis | Status: APPROVED_FOR_MARKETING